Loading organizations...

Qritive is a technology company.
Qritive develops an AI-powered diagnostic platform assisting pathologists in cancer diagnosis via microscopy image and patient data analysis. This technology integrates into pathology workflows, improving accuracy, efficiency, and consistency. It provides reliable, user-friendly AI tools designed to enhance cancer diagnosis and advance health equity.
Founded in 2017 by Aneesh Sathe and Kaveh Taghipour, Qritive emerged from recognizing pathology's persistent challenges. Their insight focused on leveraging intelligent technology to resolve slow turnaround times, inconsistent diagnoses, and workflow inefficiencies, redefining cancer diagnosis and management.
The platform benefits pathologists with increased efficiency and confidence, supporting researchers in data generation. Healthcare management utilizes Qritive's tools to strengthen diagnostic decisions and optimize care delivery. The company's vision centers on continuous innovation, delivering AI solutions that improve cancer diagnosis and promote global health equity.
Qritive has raised $8.0M across 1 funding round.
Qritive has raised $8.0M in total across 1 funding round.
Qritive has raised $8.0M in total across 1 funding round.
Qritive's investors include MassMutual Ventures, Lightspeed India Partners, Chinnu Senthilkumar, Kaixin Tan.
Qritive is a Singapore-based technology company founded in 2017 that develops AI-powered digital pathology solutions to enhance cancer diagnosis accuracy, speed, and accessibility.[1][2][3] Its flagship platform, Pantheon, digitizes pathology workflows with tools for case management, slide viewing, AI analysis, telepathology, synoptic reporting, and integration with laboratory information systems (LIS), serving pathologists, labs, hospitals, and researchers globally.[2][3] The company addresses critical challenges like pathologist shortages and diagnostic delays by providing rapid AI insights for cancers such as colon, prostate, and lymph node, with approvals in Singapore and Europe; it recently raised $7.5M to fuel global expansion, more approvals, and product enhancements.[2][3]
Qritive's growth includes offices in the US and India, a network of 400+ pathologists, 10+ partners, and AI trained on 400K images, positioning it in the booming AI diagnostics market projected to reach $8B by decade's end amid aging populations and tech investments.[2][3]
Qritive emerged from a mission to transform pathology and improve cancer diagnosis through AI, founded in 2017 in Singapore with collaborations like Singapore General Hospital for validation.[1][2][4] While specific founders are not detailed in available sources, the leadership includes a Chief Technology Officer & Co-Founder and Head Chief Medical Officer for Operations (India), reflecting expertise in AI and healthcare.[6] The idea stemmed from unmet needs in pathology—such as slow, error-prone manual processes and global pathologist shortages—driving the creation of vendor-agnostic, clinical-grade tools for faster interpretations "within seconds."[2][4]
Early traction came via regulatory approvals in Singapore and Europe, partnerships with entities like Metropolis Healthcare and Sectra, and backing from investors including Entrepreneurs First, MassMutual Ventures, SEEDS Capital, and Exfinity Venture Partners, culminating in the $7.5M round for scaling.[2][3][5]
Qritive stands out in AI pathology through these key strengths:
Qritive rides the AI diagnostics wave in healthcare, targeting digital pathology amid a global pathologist shortage and rising cancer burdens from aging populations.[2] Its timing aligns with surging investments in AI medical imaging—market growth to $8B by 2030—and regulatory momentum, as seen in its Singapore/Europe approvals and expansion plans.[2] Favorable forces include ecosystem compatibility with scanners and LIS, enabling telepathology to bridge urban-rural gaps, and collaborations with hospitals/pharma for real-world validation.[1][3]
By accelerating diagnoses and supporting research, Qritive influences the ecosystem like competitors Paige and TRIBVN Healthcare, fostering AI adoption, health equity, and collaborative care across borders.[1][2]
Qritive is primed for accelerated growth, leveraging its $7.5M funding for regulatory wins (e.g., US/FDA), platform expansions, and deeper global penetration via its pathologist network.[2] Trends like AI integration in labs, telehealth booms, and precision oncology will propel it, potentially capturing share in the $8B market while addressing shortages.[2] Its influence may evolve into a standard for collaborative pathology, enhancing outcomes and inspiring similar AI-health hybrids—transforming diagnostics from a bottleneck to a strength, as its founding purpose envisioned.[3][4]
Qritive has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2023 | $8.0M Series A | MassMutual Ventures | Lightspeed India Partners, Chinnu Senthilkumar, Kaixin Tan |